# Expert Review Panel: AI-Accelerated Biological Discovery Model v0.5

**Review Date:** January 13, 2026
**Model Version:** 0.5 (Multi-Type AI + Therapeutic Areas)
**Review Type:** Comprehensive 6-Expert Panel

---

## PANEL COMPOSITION

### Returning Reviewers (from v0.4.1)
1. **Dr. Sarah Chen** - Computational Systems Biologist (Stanford)
2. **Dr. Marcus Thompson** - Pharmaceutical R&D Strategy (ex-Pfizer VP)
3. **Dr. Elena Vasquez** - AI/ML for Drug Discovery (Google DeepMind)
4. **Dr. James Okonkwo** - Regulatory Science & Clinical Trials (FDA, retired)

### New Reviewers (Communication & Visualization)
5. **Dr. Rachel Kim** - Scientific Communication & Data Journalism (MIT Media Lab)
6. **Dr. David Nakamura** - Information Visualization & Human-Computer Interaction (Georgia Tech)

---

## REVIEWER 5: DR. RACHEL KIM
*Scientific Communication & Data Journalism, MIT Media Lab*

### Background
- 15 years experience translating complex scientific findings for diverse audiences
- Former science editor at Nature and The Atlantic
- Expert in narrative structure for technical papers
- Focus: Making models understandable to policymakers and public

### Overall Assessment: **B+ (Good, needs communication refinement)**

### Positive Observations

**P1: Strong Core Narrative**
> "The central thesis - 'physical bottlenecks limit AI acceleration' - is compelling and counterintuitive. This challenges the hype narrative effectively."

**P2: Clear Scenario Structure**
> "The three-scenario approach (pessimistic/baseline/optimistic) is intuitive for policymakers. Everyone can find their mental model represented."

**P3: Therapeutic Area Differentiation**
> "Excellent addition in v0.5. Saying 'Oncology will benefit most, CNS least' is immediately actionable for funding agencies."

### Critical Feedback

**C1: Jargon Overload in Key Metrics**
> "Terms like 'equivalent years of progress' and 'effective service rate' are abstract. A reader asks: 'What does 93.5 equivalent years MEAN for patients?'"

**Recommendation:** Add concrete translations:
- "93.5 equivalent years = ~3-4x the normal pace of drug approvals"
- "By 2050, we could see 50-60 new breakthrough therapies vs ~15-20 at current pace"

**C2: Missing Human Stakes**
> "The model is technically rigorous but emotionally flat. No mention of patient outcomes, disease burden, or lives saved."

**Recommendation:** Include a "So What?" section with:
- Estimated additional therapies approved by 2050
- Potential diseases with viable treatments (Alzheimer's, rare cancers)
- Patient population impact estimates

**C3: Cognitive Load in Figures**
> "Many figures require expert-level interpretation. The summary dashboard has 6+ panels - overwhelming for non-specialists."

**Recommendation:** Create a "Executive Summary" single-panel figure:
- One key metric (e.g., acceleration factor)
- One timeline (when bottlenecks shift)
- One comparison (therapeutic areas)

**C4: Uncertainty Communication Problem**
> "Confidence intervals like [70, 115] are precise but meaningless to policymakers. They don't think in ranges."

**Recommendation:** Use probabilistic statements:
- "There's an 80% chance we see 70-115 equivalent years by 2050"
- "Even in pessimistic scenarios, acceleration exceeds 2x"

**C5: Missing Failure Modes Discussion**
> "What could make this model WRONG? Readers need to understand limitations upfront, not buried in appendices."

**Recommendation:** Add prominent "Key Assumptions and Risks" section:
- What if AI progress stalls?
- What if regulatory frameworks don't adapt?
- What if data quality issues persist?

### Specific Visualization Feedback

| Figure | Issue | Recommendation |
|--------|-------|----------------|
| fig6_cumulative_progress | Y-axis "equivalent years" unclear | Add annotation: "2x baseline = discoveries happen twice as fast" |
| fig7_therapeutic_comparison | 5 lines hard to distinguish | Use small multiples or highlight key comparison (Oncology vs CNS) |
| fig_tornado_improved | Specialist-only format | Add plain-English summary: "Phase II success rate matters most" |
| summary_dashboard | Information overload | Create simplified 2-panel version for executive audiences |

### Priority Recommendations (Communication)

| Priority | Recommendation | Impact |
|----------|----------------|--------|
| **HIGH** | C1: Add concrete outcome translations | Accessibility |
| **HIGH** | C3: Create executive summary figure | Policymaker reach |
| **MEDIUM** | C2: Add patient impact estimates | Emotional resonance |
| **MEDIUM** | C4: Reframe uncertainty communication | Decision usefulness |
| **LOW** | C5: Prominent limitations section | Credibility |

---

## REVIEWER 6: DR. DAVID NAKAMURA
*Information Visualization & Human-Computer Interaction, Georgia Tech*

### Background
- 20 years in scientific visualization for complex systems
- Author of "Visual Clarity: Designing for Understanding"
- Consulted for CDC, WHO on pandemic data visualization
- Focus: Making multi-dimensional data intuitive

### Overall Assessment: **B (Good foundations, visualization needs work)**

### Positive Observations

**P1: Appropriate Chart Type Selection**
> "Line charts for time series, bar charts for comparisons, heatmaps for multi-dimensional data - fundamentally sound choices."

**P2: Consistent Color Scheme**
> "The scenario coloring (pessimistic=blue, baseline=green, optimistic=orange) is maintained across figures. Good for cognitive continuity."

**P3: Uncertainty Bands**
> "Fan charts with confidence intervals are the right approach for Monte Carlo results. Professional quality."

### Critical Feedback

**C1: Visual Hierarchy Missing**
> "All figures appear equally important. No clear progression from 'start here' to 'deep dive.' Reader doesn't know where to focus."

**Recommendation:** Establish figure hierarchy:
- **Hero Figure**: Single most important visualization (progress trajectory)
- **Supporting Figures**: Key details (bottlenecks, therapeutic areas)
- **Technical Appendix**: Sensitivity, Monte Carlo details

**C2: Color Accessibility Issues**
> "Red-green color combinations fail for ~8% of male readers with color vision deficiency. Current palette not accessible."

**Recommendation:** Use colorblind-safe palette:
- Replace red/green with blue/orange
- Add pattern fills for print accessibility
- Test with Coblis colorblind simulator

**C3: Axis Label Readability**
> "Font sizes too small in multi-panel figures. 'Effective Service Rate' barely legible in fig3_service_rates."

**Recommendation:**
- Minimum 10pt font for axis labels
- 12pt for titles
- Consider splitting dense figures into pages

**C4: Annotation Density**
> "Figures lack explanatory annotations. Bottleneck transition points should be called out, not left for reader to discover."

**Recommendation:** Add strategic annotations:
```
fig4_bottleneck_timeline:
  - Arrow pointing to S7→S8 transition: "Bottleneck shifts from Phase II to Phase III around 2042"
  - Shaded region: "Critical window for policy intervention"
```

**C5: Interactive Potential Unexploited**
> "Static figures work for papers but miss interactive exploration opportunities. Web version could add tooltips, filtering."

**Recommendation:** For supplementary materials:
- Plotly/Bokeh interactive versions
- Slider for scenario parameters
- Hover details for data points

**C6: Dashboard Cognitive Load**
> "summary_dashboard.png has 6 panels with different scales, units, and time ranges. Exceeds working memory limits (~4 chunks)."

**Recommendation:** Redesign dashboard:
- Maximum 4 panels per view
- Consistent time axis across all panels
- Progressive disclosure (overview → detail)

**C7: Missing Visual Metaphor**
> "The 'bottleneck' concept is perfect for visualization but underused. Show a literal pipeline narrowing at Phase II."

**Recommendation:** Create pipeline schematic:
- Visual width proportional to throughput
- Animated version showing flow and congestion
- Before/after AI comparison

### Specific Figure Redesigns

**Priority Redesign 1: Progress Trajectory (Hero Figure)**
```
Current: fig6_cumulative_progress
Issues: Multiple lines, no context, technical axis

Proposed Redesign:
- Single panel with baseline trajectory prominent
- Pessimistic/Optimistic as subtle bands
- Y-axis: "Speed of Discovery (1x = today's pace)"
- Key milestones annotated: "2x by 2035", "3x by 2045"
- Inset: What 2x means in therapy approvals
```

**Priority Redesign 2: Bottleneck Timeline (Supporting)**
```
Current: fig4_bottleneck_timeline
Issues: Dense, multiple scenarios, no clear takeaway

Proposed Redesign:
- Baseline scenario only (others in appendix)
- Pipeline diagram showing bottleneck location over time
- Color gradient from red (bottleneck) to green (not limiting)
- Clear label: "Phase II remains bottleneck until 2040s"
```

**Priority Redesign 3: Therapeutic Comparison (Key Insight)**
```
Current: fig7_therapeutic_comparison + fig7b_therapeutic_bars
Issues: Two figures for one message, redundant

Proposed Redesign:
- Single slope chart: Oncology vs CNS trajectories
- Annotation: "Oncology: 69% more progress than CNS by 2050"
- Small multiples for all 5 areas if needed
```

### Technical Specifications for Figures

| Aspect | Current | Recommended |
|--------|---------|-------------|
| Resolution | 300 DPI | 300 DPI (good) |
| Color palette | Matplotlib defaults | Viridis/Cividis (colorblind-safe) |
| Font | Sans-serif mix | Consistent Arial/Helvetica |
| Axis labels | 8-10pt | 10-12pt minimum |
| Figure size | Variable | Standardize to journal specs |
| White space | Cramped | 15% margin minimum |

### Priority Recommendations (Visualization)

| Priority | Recommendation | Impact |
|----------|----------------|--------|
| **HIGH** | C1: Establish figure hierarchy | Comprehension |
| **HIGH** | C7: Create pipeline schematic | Intuitive understanding |
| **HIGH** | C4: Add strategic annotations | Self-explanatory figures |
| **MEDIUM** | C2: Colorblind-safe palette | Accessibility |
| **MEDIUM** | C6: Redesign dashboard | Reduce cognitive load |
| **LOW** | C5: Interactive supplements | Engagement |
| **LOW** | C3: Font size standards | Readability |

---

## RETURNING REVIEWERS: V0.5 UPDATE FEEDBACK

### Dr. Sarah Chen (Computational Systems Biology)

**v0.5 Response to v0.4.1 Feedback:**

> "Excellent implementation of multi-type AI. The g_c=0.60 / g_r=0.30 / g_s=0.55 split is well-calibrated to Epoch AI data. Therapeutic area differentiation addresses my B1 concern from v0.4.1 review."

**New Concerns for v0.6:**

**C1: Cross-stage dependencies still missing**
> "Wet lab capacity constraints affect multiple downstream stages. Current model treats stages as independent queues."

**C2: Data quality feedback loop**
> "AI-generated hypotheses → more experiments → more data → better AI. This virtuous cycle isn't captured yet."

**Recommendation:** v0.6 should add:
- Data quality module D(t)
- Cross-stage resource constraints
- Rework/iteration probabilities

---

### Dr. Marcus Thompson (Pharmaceutical R&D Strategy)

**v0.5 Response:**

> "Therapeutic area differentiation is spot-on. Oncology having highest AI potential (M_mult=1.4) aligns with industry reality - biomarker-driven trials are already standard. CNS being hardest matches our experience."

**New Concerns:**

**C1: Missing commercial viability filter**
> "Not all scientifically successful drugs reach patients. Market size, manufacturing complexity, pricing - none modeled."

**C2: Geographic variation**
> "US FDA, EU EMA, China NMPA have different approval timelines. Model assumes single regulatory path."

**Recommendation:** Consider adding:
- Market viability probability per therapeutic area
- Regional regulatory variation (US/EU/China scenarios)

---

### Dr. Elena Vasquez (AI/ML for Drug Discovery)

**v0.5 Response:**

> "Multi-type AI is a significant improvement. The weighted combination per stage (e.g., wet lab = 70% robotic) better reflects real-world deployment patterns."

**New Concerns:**

**C1: AI capability correlation ignored**
> "Cognitive, robotic, and scientific AI capabilities aren't independent. Advances in transformers benefit all three types."

**C2: Missing AI safety/alignment considerations**
> "Regulatory bodies may impose AI-specific requirements that slow deployment, especially for clinical decision-making."

**Recommendation:** Add:
- Correlation structure between AI types in Monte Carlo
- AI regulatory burden parameter (scenario-dependent)

---

### Dr. James Okonkwo (Regulatory Science)

**v0.5 Response:**

> "Therapeutic area success rates from Wong et al. (2019) are appropriate. Oncology's higher success and CNS's challenges are well-established in regulatory data."

**New Concerns:**

**C1: Regulatory adaptation not modeled**
> "FDA is actively updating AI guidance. Real-Time Oncology Review, Breakthrough Therapy designation - these accelerate approval."

**C2: Post-market surveillance burden**
> "AI-accelerated approvals may require more extensive Phase IV monitoring, adding hidden time costs."

**Recommendation:** Model regulatory dynamics:
- Decreasing approval times as AI proves safe
- Post-market monitoring requirements
- Accelerated pathways (Breakthrough, Fast Track) as scenario variations

---

## CONSOLIDATED IMPROVEMENT RECOMMENDATIONS

### Tier 1: CRITICAL (Implement for v0.6)

| ID | Category | Recommendation | Owner | Complexity |
|----|----------|----------------|-------|------------|
| T1.1 | Communication | Add concrete outcome translations (therapies, patients) | Rachel Kim | Low |
| T1.2 | Visualization | Create executive summary figure (hero visualization) | David Nakamura | Medium |
| T1.3 | Visualization | Establish figure hierarchy (hero → supporting → technical) | David Nakamura | Low |
| T1.4 | Model | Add data quality module D(t) | Sarah Chen | High |
| T1.5 | Communication | Reframe uncertainty for policymakers | Rachel Kim | Low |

### Tier 2: HIGH PRIORITY (Implement for v0.7)

| ID | Category | Recommendation | Owner | Complexity |
|----|----------|----------------|-------|------------|
| T2.1 | Visualization | Colorblind-safe palette across all figures | David Nakamura | Low |
| T2.2 | Visualization | Add strategic annotations to key figures | David Nakamura | Medium |
| T2.3 | Model | Cross-stage resource constraints | Sarah Chen | High |
| T2.4 | Model | AI type correlation in Monte Carlo | Elena Vasquez | Medium |
| T2.5 | Communication | Add patient impact section with estimates | Rachel Kim | Medium |

### Tier 3: MEDIUM PRIORITY (Implement for v0.8-0.9)

| ID | Category | Recommendation | Owner | Complexity |
|----|----------|----------------|-------|------------|
| T3.1 | Visualization | Create pipeline schematic with visual bottleneck | David Nakamura | High |
| T3.2 | Model | Geographic regulatory variation (US/EU/China) | James Okonkwo | High |
| T3.3 | Model | Commercial viability filter | Marcus Thompson | Medium |
| T3.4 | Model | Regulatory adaptation dynamics | James Okonkwo | Medium |
| T3.5 | Visualization | Interactive web version | David Nakamura | High |

### Tier 4: LOW PRIORITY (Consider for v1.0)

| ID | Category | Recommendation | Owner | Complexity |
|----|----------|----------------|-------|------------|
| T4.1 | Model | AI regulatory burden parameter | Elena Vasquez | Low |
| T4.2 | Model | Post-market surveillance costs | James Okonkwo | Medium |
| T4.3 | Visualization | Animated pipeline visualization | David Nakamura | High |
| T4.4 | Communication | Public-facing summary document | Rachel Kim | Medium |

---

## IMPLEMENTATION PLAN

### Phase 1: Communication & Visualization Overhaul (v0.5.1)
**Timeline:** 1-2 days
**Focus:** Low-hanging fruit from communication reviewers

1. **Outcome Translations**
   - Add "What This Means" callouts to key figures
   - Calculate estimated therapy approvals by 2050
   - Create glossary of key terms

2. **Figure Hierarchy**
   - Designate fig6_cumulative_progress as hero figure
   - Redesign with annotations and accessible axis labels
   - Create simplified 2-panel executive summary

3. **Accessibility Updates**
   - Implement colorblind-safe palette (Viridis/Cividis)
   - Increase font sizes to minimum 10pt
   - Add pattern fills for key distinctions

### Phase 2: Data Quality Module (v0.6)
**Timeline:** 3-5 days
**Focus:** Core model improvement

1. **D(t) Implementation**
   - Data quality index growing with AI capability
   - Elasticity parameter per stage
   - AI both consumes and produces data

2. **Cross-stage Interactions**
   - Shared wet lab capacity constraints
   - Data quality affects all downstream stages

3. **Updated Visualizations**
   - Data quality trajectory plot
   - Impact on stage-specific acceleration

### Phase 3: Advanced Modeling (v0.7-0.8)
**Timeline:** 1-2 weeks
**Focus:** Expert recommendations

1. **AI Type Correlations**
   - Correlated sampling in Monte Carlo
   - Sensitivity analysis for correlation strength

2. **Geographic Variation**
   - US/EU/China regulatory scenarios
   - Impact on global therapy availability

3. **Pipeline Iteration**
   - Rework probabilities
   - Semi-Markov process implementation

### Phase 4: Paper Finalization (v0.9-1.0)
**Timeline:** 2-3 weeks
**Focus:** Publication readiness

1. **Policy Analysis**
   - Intervention ROI rankings
   - Timing recommendations

2. **Full Uncertainty Quantification**
   - 10,000 sample Monte Carlo
   - Sobol sensitivity indices

3. **Interactive Supplements**
   - Web-based exploration tool
   - Downloadable model and data

---

## REVIEWER SIGN-OFF

| Reviewer | Approval | Key Concern Addressed |
|----------|----------|----------------------|
| Dr. Sarah Chen | Conditional | Awaiting D(t) module |
| Dr. Marcus Thompson | Conditional | Need geographic variation |
| Dr. Elena Vasquez | Conditional | AI correlation structure needed |
| Dr. James Okonkwo | Conditional | Regulatory dynamics wanted |
| Dr. Rachel Kim | Conditional | Communication improvements critical |
| Dr. David Nakamura | Conditional | Visualization overhaul needed |

---

## APPENDIX: DETAILED FIGURE SPECIFICATIONS

### A1: Hero Figure - Progress Trajectory (Redesigned)

```
Filename: fig_hero_progress.png
Dimensions: 8" x 6" (journal single-column)
DPI: 300

Layout:
- Main panel: Baseline trajectory with uncertainty band
- Y-axis: "Discovery Pace (1x = 2024 baseline)" - range 0-5x
- X-axis: Year 2024-2050
- Annotations:
  - "2x by 2035" with arrow
  - "3x by 2043" with arrow
  - "Bottleneck shifts" highlighted region

Color:
- Baseline: #1f77b4 (blue)
- Uncertainty: #1f77b4 with 20% opacity
- Annotations: #333333 (dark gray)

Typography:
- Title: Arial Bold 14pt
- Axis labels: Arial 12pt
- Annotations: Arial 10pt
```

### A2: Executive Summary Figure (New)

```
Filename: fig_executive_summary.png
Dimensions: 10" x 4" (journal full-width)
DPI: 300

Layout: 2-panel horizontal
- Left panel: Key metric over time
- Right panel: Therapeutic area comparison

Left Panel:
- Y-axis: "Speed of Scientific Progress"
- Single line with milestone annotations
- Inset: "By 2050: 50-60 new therapies vs 15-20 today"

Right Panel:
- Horizontal bar chart
- Therapeutic areas ranked by 2050 progress
- Color gradient from high (green) to low (red/orange)
```

---

*Review completed: January 13, 2026*
*Next review scheduled: After v0.6 implementation*
